Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Investigating mechanisms of cell death in Alzheimer's disease and prion disorders

FY 2019-20

Summary
"A reduction in the levels of the cellular prion protein (PrPC) is expected to ameliorate cellular toxicity in both Alzheimer's disease (AD) and prion diseases. The latter are invariably fatal diseases that include Creutzfeldt-Jakob disease in humans and bovine spongiform encephalopathy (BSE), also known as 'Mad Cow Disease', in cattle. To identify a rational method for reducing PrPC levels, the Schmitt-Ulms group has been studying the evolution, function and molecular environment of PrPC for more than ten years. These efforts culminated recently in a rational small molecule-based strategy that accomplishes a profound ( 50%) reduction of PrPC levels. The current proposal is based on an academic-industry partnership between the Schmitt-Ulms group, Cyclica (a Toronto-based company), and Charles-River Laboratories (CRL; a major contract research organization. It will allow me to work in a team that will apply cell-based screens, pharmacological and toxicological analyses of optimized derivatives of our lead compound. These derivatives will emerge from a machine learning-based discovery platform developed by Cyclica and will be synthesized under the guidance of leading-edge medicinal chemistry expertise provided by CRL. Its overarching goal is to identify an optimized small molecule lead compound that exhibits most favorable characteristics for the intended indication. Its success will represent an indispensable milestone for moving this treatment approach to the clinic."
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
428786
Name
Eid Shehab
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Investigating mechanisms of cell death in Alzheimer's disease and prion disorders
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Prion Disease
Abstract
"A reduction in the levels of the cellular prion protein (PrPC) is expected to ameliorate cellular toxicity in both Alzheimer's disease (AD) and prion diseases. The latter are invariably fatal diseases that include Creutzfeldt-Jakob disease in humans and bovine spongiform encephalopathy (BSE), also known as 'Mad Cow Disease', in cattle. To identify a rational method for reducing PrPC levels, the Schmitt-Ulms group has been studying the evolution, function and molecular environment of PrPC for more than ten years. These efforts culminated recently in a rational small molecule-based strategy that accomplishes a profound ( 50%) reduction of PrPC levels. The current proposal is based on an academic-industry partnership between the Schmitt-Ulms group, Cyclica (a Toronto-based company), and Charles-River Laboratories (CRL; a major contract research organization. It will allow me to work in a team that will apply cell-based screens, pharmacological and toxicological analyses of optimized derivatives of our lead compound. These derivatives will emerge from a machine learning-based discovery platform developed by Cyclica and will be synthesized under the guidance of leading-edge medicinal chemistry expertise provided by CRL. Its overarching goal is to identify an optimized small molecule lead compound that exhibits most favorable characteristics for the intended indication. Its success will represent an indispensable milestone for moving this treatment approach to the clinic."
Competitiondate
201912
Approvedterm2
1 yr 0 mth
Pinamesdelim
Eid, Shehab
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~